Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data after the market closes on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $4.37 million for the quarter.
Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($1.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.40) by $0.40. The business had revenue of $3.44 million during the quarter, compared to analyst estimates of $2.53 million. On average, analysts expect Verrica Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Verrica Pharmaceuticals Price Performance
Shares of Verrica Pharmaceuticals stock traded up $0.24 on Friday, hitting $6.35. 10,701 shares of the company's stock traded hands, compared to its average volume of 44,052. The company has a fifty day moving average of $6.59 and a two-hundred day moving average of $6.06. Verrica Pharmaceuticals has a one year low of $3.82 and a one year high of $58.20. The company has a market capitalization of $58.73 million, a price-to-earnings ratio of -0.53 and a beta of 1.92.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on the stock. Needham & Company LLC reiterated a "hold" rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, May 14th. Wall Street Zen raised shares of Verrica Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat, Verrica Pharmaceuticals has an average rating of "Hold" and a consensus price target of $80.00.
Read Our Latest Stock Analysis on Verrica Pharmaceuticals
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the business. Bank of America Corp DE boosted its holdings in Verrica Pharmaceuticals by 347.5% during the 4th quarter. Bank of America Corp DE now owns 143,818 shares of the company's stock worth $101,000 after acquiring an additional 111,678 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Verrica Pharmaceuticals by 23.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 139,055 shares of the company's stock worth $61,000 after buying an additional 26,308 shares in the last quarter. Invesco Ltd. boosted its position in Verrica Pharmaceuticals by 64.8% in the first quarter. Invesco Ltd. now owns 74,388 shares of the company's stock worth $33,000 after purchasing an additional 29,256 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in shares of Verrica Pharmaceuticals by 306.7% during the 1st quarter. AQR Capital Management LLC now owns 58,711 shares of the company's stock valued at $26,000 after purchasing an additional 44,275 shares during the last quarter. 42.45% of the stock is owned by institutional investors.
Verrica Pharmaceuticals Company Profile
(
Get Free Report)
Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.
Featured Articles

Before you consider Verrica Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verrica Pharmaceuticals wasn't on the list.
While Verrica Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.